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Abstract
Ovarian cancer is routinely treated with surgery and platinum-based chemotherapy. Resistance is a major obstacle in the efficacy of this chemo-
therapy regimen and the ability to identify those patients at risk of developing resistance is of considerable clinical importance. The expression of
calpain-1, calpain-2 and calpastatin were determined using standard immunohistochemistry on a tissue microarray of 154 primary ovarian carcino-
mas from patients subsequently treated with platinum-based adjuvant chemotherapy. High levels of calpain-2 expression was significantly associ-
ated with platinum resistant tumours (P = 0.031). Furthermore, high expression of calpain-2 was significantly associated with progression-free
(P = 0.049) and overall survival (P = 0.006) in this cohort. The association between calpain-2 expression and overall survival remained significant
in multivariate analysis accounting for tumour grade, stage, optimal debulking and platinum sensitivity (hazard ratio = 2.174; 95% confidence
interval = 1.144–4.130; P = 0.018). The results suggest that determining calpain-2 expression in ovarian carcinomas may allow prognostic strati-
fication of patients treated with surgery and platinum-based chemotherapy. The findings of this study warrant validation in a larger clinical cohort.
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Introduction
Ovarian cancer is the eighth most common cancer in females, and
the seventh leading cause of cancer mortality in women worldwide
[1]. Treatment for all stages of ovarian cancer principally consists of
surgery and platinum-based chemotherapy. Despite initial sensitivity
to platinum-based agents some tumours become resistant, or are
already intrinsically resistant to the treatment. Platinum resistance is
a major obstacle in the efficacy of platinum-based chemotherapy regi-
mens, and biomarkers of platinum-based chemotherapy response are
therefore of substantial clinical interest. There are a number of studies
that have investigated biomarkers that have the potential to stratify
ovarian cancer patients based on their response to platinum-based
chemotherapy. Tissue expression of vascular endothelial growth fac-
tor-A is significantly higher in patients who develop chemotherapy-
resistant disease and have adverse overall survival [2] and high
nuclear and low cytoplasmic expression of thioredoxin and low
expression of metallothionein has been shown to be associated with
increased progression-free and overall survival in ovarian cancer
patients treated with platinum-based chemotherapy; but is not associ-
ated with platinum resistance [3]. Platinum-based agents are believed
to instigate cell death following induction of DNA adducts, and there
is accumulating in vitro evidence that platinum-induced apoptosis can
be mediated, in part, by calpains [4–6].
The calpain system is an important group of proteases, with micro
(l)-calpain and milli (m)-calpain being the most widely studied family
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members [7]. These neutral cysteine proteases are responsible for
the controlled proteolysis of a number of cellular substrates important
in cellular migration, survival and apoptosis. Both l-calpain and m-
calpain are composed of a large 80-kDa catalytic subunit, calpain-1
and calpain-2, respectively, and have a common small 28-kDa regula-
tory subunit. The enzymes require calcium for their activation, and
l-calpain and m-calpain are named for the in vitro calcium concentra-
tion required for their activity [7]. There are several mechanisms by
which the calcium concentration required for activation can be low-
ered including protein autolysis and interaction with membrane phos-
pholipids [8, 9]. Furthermore, m-calpain can be phosphorylated by
ERK and protein kinase Cι, which has been shown to alter cell adhe-
sion and migration [10, 11]. Calpastatin is the endogenous inhibitor
of l-calpain and m-calpain and can reversibly inhibit up to four cal-
pain heterodimers, with inhibitory action requiring calcium-induced
structural changes to calpain [12–14]. Recent evidence has indicated
the importance of calpain in cancer progression, in particular during
cellular migration, and has highlighted a potential role of the calpain
system in altering the response to certain cancer therapies [15].
In vitro evidence in ovarian cancer cell lines suggests that calcium
release following cisplatin treatment increases calpain activity which
can cleave p73 [5]. Importantly, Al-Bahlani et al. (2011), showed that
cells with reduced calpain activity, or increased p73 were less sensi-
tive to cisplatin treatment [5].
Due to the importance of calpain activity in tumour progression,
its role in other tumour types, and in vitro evidence suggesting a role
in the response of ovarian cancer cell lines to cisplatin the aims of the
current study were to investigate the expression levels of calpastatin,
calpain-1 (l-calpain) and calpain-2 (m-calpain) in tumours from ovar-
ian cancer patients treated with platinum-based adjuvant chemother-
apy. Furthermore, it aims to determine the importance of calpain
expression in terms of associations with clinicopathological variables
and the clinical outcome of the patients. Importantly a measure of
response to platinum-based chemotherapy was available for all the
patients in the form of platinum resistance or sensitivity determined
clinically, defined as those patients that progressed during first line
chemotherapy.
Materials and methods
Clinical cohort
The clinical cohort comprised of 154 patients with primary ovarian can-
cer treated with carboplatin-based adjuvant chemotherapy at Notting-
ham University Hospitals between 2000 and 2007. Forty-two (65/154)
of patients received carboplatinum alone, whereas the remaining
patients received combined platinum regimens, including 78 of 89
(88%) with paclitaxel and the remaining 11 of 89 (12%) patients receiv-
ing alternate combinations (carboplatin in combination with gemcita-
bine, topotecan or liposomal doxorubicin) dependent upon their
inclusion in concurrent clinical trials (ICON trial). Ethical approval was
obtained from the Derbyshire ethics committee (06/Q2401/153). Clinico-
pathological data such as tumour grade and stage were retrospectively
recorded for the cohort and are shown in Table 1. The mean age of the
cohort was 59.7 years ranging in years from 33 to 87. Progression-free
survival was calculated from the date of the initial surgery to disease
progression or from the date of the initial surgery to the last date
known to be progression-free for those censored. Overall survival time
was calculated from the date of the initial surgery to death or from date
of the initial surgery to last date known to be alive for those censored.
The study was retrospectively analysed up to 30 April 2009 and at this
point 51% (79/154) of patients had died and 57% (85/150) of patients
had progressive disease. The median follow-up for this study was
48 months. Platinum resistant cases were defined as those patients that
progressed with first-line platinum-based chemotherapy during treat-
ment, or within 6 months of treatment. Thirty-two% (50/154) of
patients had platinum-resistant disease. This study is reported in con-
cordance with REMARK criteria [16]
TMA construction and immunohistochemistry
The ovarian cancer tissue microarrays (TMAs) were prepared as
described previously, with two tumour tissue cores assessed per patient
[3]. The tumour cores that were assessed in this study was not selected
upon tumour location, but that they were representative of the tumour.
Four micrometre sections of the TMA were mounted on poly-L-lysine
coated slides. Immunohistochemistry was performed using a similar
method to that previously described for breast cancer using the primary
antibodies; mouse anti-calpastatin, mouse anti-calpain-1 and rabbit anti-
calpain-2 [all Chemicon (Millipore, MA, USA) clones PI-11, P-6 and rabbit
polyclonal AB1625, respectively, with specificity confirmed by Western
blotting] [17, 18]. Briefly slides were deparaffinized in histolene followed
by rehydration in a series of ethanol baths (100%, 90%, 70%, 50% and
30% in water). Antigen retrieval was performed in pre-heated 0.01 mol/l
sodium citrate buffer (pH6) in a microwave at 400 W for 10 min. Endog-
enous peroxidase activity was blocked over 10 min. in 0.01% hydrogen
peroxide in methanol. Staining was achieved using the Vectastain Elite
ABC kit (universal), containing blocking serum, biotinylated secondary
antibody and ABC reagent (Vector Laboratories, Peterborough, UK). Pri-
mary antibodies were diluted in blocking serum (calpastatin 1:15,000;
calpain-1 1:2500; calpain-2 1:2500) and applied to the tissue for 1 hr at
room temperature. Immunohistochemical reactions were developed with
3,3′ diaminobenzidine as the chromogenic peroxidase substrate (Dako,
Glostrup, Denmark). Sections were then counterstained with Gills for-
mula Haematoxylin (Vector Laboratories), dehydrated and fixed in histo-
lene prior to mounting with DPX. Breast tumour composite sections
which comprised of six stage 1 breast tumours of grade 1–3 were
included as positive and negative controls with each run, with the nega-
tive control having primary antibody substituted for PBS.
Assessment of staining was conducted after scanning of the slides
with a Nanozoomer Digital Pathology Scanner (Hamamatsu Photonics,
Hamamatsu City, Japan) at 209 magnification. Calpastatin, calpain-1
and calpain-2 expression in tumour cells was manually assessed using
an immunohistochemical H-score as described previously [17]. Briefly,
staining intensity of tumour cells was assessed as; none (0), weak (1),
medium (2) and strong (3) over the percentage area of each staining
intensity. H-scores were calculated by multiplying the percentage area
by the intensity grade (H-score range 0–300). A minimum of 30% of
tissue cores were examined by a second independent assessor, with
the majority of patients having one tissue core assessed by both scor-
ers. Both assessors were blinded to each other’s scores and clinico-
pathologic criteria and there was good concordance between both
scorers (single measure intra-class correlations greater than 0.75). Each
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Table 1 Associations between calpastatin, calpain-1 and calpain-2 protein expression and various clinicopathological variables. The frequency
of observed clinicopathological variables is noted next to the variable subgroup. The P-values are resultant from Pearson chi-square test of
association (v2) or Fisher’s exact test in a 2 9 2 table if a cell count was less than 5 (indicated by *). Significant P-values are indicated by
bold font
Variable
Calpastatin Calpain-1 Calpain-2
Low High P-value Low High P-value Low High P-value
Pathology
Serous (n = 91) 11 56 <0.001 5 62 0.003 13 55 <0.001
Mucinous (n = 11) 5 3 0 8 4 4
Endometrioid (n = 29) 9 15 7 18 9 15
Clear cell (n = 20) 11 6 7 10 14 3
Others (n = 3) 2 0 0 1 0 1
Grade
1 (n = 19) 5 10 0.556 2 13 0.925 4 10 0.313
2 (n = 22) 3 12 2 12 3 13
3 (n = 113) 30 58 15 74 33 55
Debulking surgery
Optimal (n = 90) 27 44 0.096 13 57 0.378 27 42 0.154
Suboptimal (n = 64) 11 36 6 42 13 36
Stage
I (n = 42) 16 19 0.105 8 27 0.637 17 17 0.103
II (n = 20) 3 11 2 12 4 10
III (n = 71) 17 37 7 46 16 38
IV (n = 21) 2 13 2 14 3 13
Chemotherapy
Carboplatin monotherapy (n = 60) 20 30 0.103 10 41 0.405 19 30 0.315
Carboplatin combination (n = 88) 17 49 9 56 20 47
Platinum sensitivity
Sensitive (n = 104) 27 54 0.698 15 66 0.419* 32 47 0.031
Resistant (n = 50) 11 26 4 33 8 31
Progression-free status
progression-free (n = 65) 22 32 0.064 10 45 0.646 23 29 0.053
progressive disease (n = 85) 15 46 9 51 17 46
Survival status
Living (n = 75) 19 43 0.703 9 54 0.566 27 34 0.014
Deceased (n = 79) 19 37 10 45 13 44
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case had two cores assessed and an average H-score calculated. The
continuous data was dichotomized for analysis using X-tile [19].
Statistical analysis
The relationship between categorized protein expression and clinico-
pathologic factors was analysed using Pearson chi-square test of asso-
ciation (v2) or Fisher’s exact test in a 2 9 2 table if a cell count was
less than 5. Overall disease specific survival curves were plotted
according to the Kaplan–Meier method and significance determined
using the log-rank test. Multivariate survival analysis was performed by
Cox Proportional hazards analysis. All differences were deemed signifi-
cant at the level of P < 0.05. Statistical analysis was performed using
SPSS 17.0 software (IBM corporation, NY, USA).
Results
Immunohistochemistry
Tissue expression of calpastatin, calpain-1 and calpain-2 was
assessed in a series of 154 ovarian cancer patients treated with plati-
num-based chemotherapy. All three proteins were mainly located in
the cytoplasm, with some granularity and heterogeneity between
adjacent tumour cells, varying from weak to intense staining. Nuclear
staining was observed quite frequently for calpastatin. Some stromal
cell staining was observed, however, this was not scored as part of
this study. Calpastatin had a mean H-score of 184 and a standard
deviation of ±67; calpain-1 had a mean H-score of 114 ± 74 and cal-
pain-2 had a mean H-score of 159 ± 47. Representative staining is
shown in photomicrographs in Fig. 1. Two cores were assessed for
each patient, with an average H-score being used for analysis. The
correlation between the two scores for each patient was evaluated
using Spearman’s rank correlation coefficient. A significant correla-
tion between the two scores for expression of calpain-1, calpain-2
and calpastatin was observed.
Relationship with clinicopathological variables
Calpastatin, calpain-1 and calpain-2 H-scores were dichotomized
using X-tile software into low and high immunoreactivity and were
tested for associations with clinicopathologic criteria. X-tile generated
cut points were as follows: calpastatin had a H-score cut point of 165
with 80 cases having a high score; calpain-1 had a H-score cut point
of 25 with 99 cases having a high score; calpain-2 had a H-score cut
point of 162 with 78 cases having a high score. A small number of
TMA cores were not assessed due to missing cores or insufficient
representative tumour. Associations between protein expression and
clinicopathological criteria are shown in Table 1. Ovarian tumours of
the serous type were associated with high expression of calpastatin
(v2 = 23.755, d.f. = 4, P < 0.001), high calpain-1 (v2=15.961, d.f. =
4, P = 0.003) and high calpain-2 (v2 = 26.02, d.f. = 4, P < 0.001).
High calpain-2 expression was associated with platinum resistant
tumours (v2 = 4.658, d.f. = 1, P = 0.031) and with death of the
patient (v2 = 6.053, d.f. = 1, P = 0.014).
Relationship with progression-free survival
At the end of the follow-up period 85 patients had developed progres-
sive-disease, with a median progression-free survival of 14 months.
The expression of calpastatin and calpain-1 was not associated with
overall or progression-free survival (Fig. 2A and B). However, high
expression of calpain-2 was significantly associated with progres-
sion-free survival (P = 0.049) (Fig. 2C). In multivariate analysis,
including grade, stage, optimal debulking and platinum sensitivity,
calpain-2 expression was not an independent marker of progression-
free survival (Table 2A). Tumour grade, stage, optimal debulking and
platinum sensitivity were included in multivariate analysis following
A B
C D
E F
Fig. 1 Representative photomicrographs of protein expression levels.
(A) low calpastatin expression (H-score 60); (B) high calpastatin expres-
sion (H-score 280); (C) low calpain-1 expression (H-score 10); (D) high
calpain-1 expression (H-score 200); (E) low calpain-2 expression (H-
score 20); (F) high calpain-2 expression (H-score 165). Photomicro-
graphs are at 109 magnification with 209 magnification inset box
where scale bar shows 50 lm.
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assessment using the Kaplan–Meier method and significance deter-
mined using the log-rank test with individual values of P = 0.004,
P < 0.001, P < 0.001, and P < 0.001 respectively.
Relationship with overall survival
At the end of the follow-up period 79 patients had died, with a median
survival of 35 months. The expression of calpastatin and calpain-1
was not associated with overall survival (Fig. 3A and B). High expres-
sion of calpain-2 was significantly associated with overall survival
(P = 0.006) (Fig. 3C). In multivariate analysis, including grade, stage,
optimal debulking and platinum sensitivity, calpain-2 expression was
independently significant for overall survival (hazard ratio = 2.174;
95% confidence interval = 1.144–4.130; P = 0.018) (Table 2B).
Tumour grade, stage, optimal debulking and platinum sensitivity were
included in multivariate analysis following assessment using the Kap-
lan–Meier method and significance determined using the log-rank test
with individual values of P = 0.008, P < 0.001, P < 0.001 and
P < 0.001 respectively.
Discussion
The expression levels of calpastatin, calpain-1 and calpain-2 were
determined in a cohort of 154 ovarian cancer patients treated with
platinum-based adjuvant chemotherapy. No prior studies have inves-
tigated the expression of calpastatin, calpain-1 and calpain-2 in ovar-
ian cancer, or have tested their association with response to
platinum-based chemotherapy in tissue samples. The expression lev-
els of these proteins have previously been investigated in breast can-
cer, with results indicating that expression of calpain-1 is associated
with relapse-free survival in HER2 positive breast cancer patients
treated with trastuzumab following adjuvant chemotherapy [17].
The calpain system, including the proteolytic enzymes l-calpain
and m-calpain and their endogenous inhibitor calpastatin, has been
implicated in cancer progression and response to therapy in a limited
number of studies and tumour types [15]. Recent in vitro evidence
has suggested that calpain activity following cisplatin treatment influ-
ences the apoptotic process by reducing p73 which acts as a pro-
apoptotic factor [5]. In the current study, high calpain-2 expression is
of clear adverse importance in ovarian cancer patients. Although the
in vitro evidence suggests calpain activity is important in cisplatin-
induced apoptosis, translational evidence suggests high calpain-2
expression is important in platinum-based therapy resistance. There
are a large number of differences between studies; the in vitro study
investigated calpain modulation in a range of ovarian cancer cell lines
at the time of treatment with cisplatin; whereas the current study doc-
uments the expression level of calpain-2 in tumours prior to treatment.
High expression of calpain-2 in the surgically excised tumour may
indicate that the tumour, and by implication any tumour cells remain-
ing after surgery, has evolved mechanisms of surviving high calpain-2
expression. In this manner, high calpain-2 expression may be benefi-
cial to cell survival by making calpain-dependent apoptosis ineffective
in the face of systemic platinum-based therapy; alternatively high
calpain-2 expression in the primary tumour may suggest that the
tumour has a higher capacity for migration, and that these tumours
may have a more aggressive phenotype. The role of calpain in altering
A
B
C
Fig. 2 Kaplan–Meier analysis of progression-free survival showing the
impact of calpastatin (A), calpain-1 (B) and calpain-2 (C) expression in
cohort of 154 patients with significance determined using the log rank
test. (A) low expression group has 37 observations and 15 events and
high expression group has 78 observations and 46 events; (B) low
expression group has 19 observations and 9 events and high expres-
sion group has 96 observations and 51 events; (C) low expression
group has 40 observations and 17 events and high expression group
has 75 observations and 46 events; where observations are the number
of observations per group and events are those patients with progres-
sive disease.
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cell migration is well established. Evidence has shown that calpain can
cleave a number of substrates involved in promoting cellular motility,
including focal adhesion kinase (FAK) and talin but also many other
substrates such as paxillin, fodrin and ezrin [20–24]. It should be
noted that this study investigated the relative protein expression levels
of calpain-1 and calpain-2, and not their activity within the tissues. As
part of future studies it would be interesting to assess calpain activity
within ovarian carcinoma tissue using antibodies against calpain-spe-
cific digestion products, however, such antibodies require validation
and characterization for use in human cancer [25, 26]. Interestingly
the cut-point for calpain-1 was lower than that of calpain-2; it remains
unclear as to why this would occur although the lower calcium con-
centration required for calpain-1 activation may mean that lower
expression levels of the protein are required.
Although there was a significant association between high calpain-
2 expression and platinum sensitivity, high calpain-2 expression was
only marginally associated with progression-free survival (P = 0.049),
but clearly associated with overall survival (P = 0.006) which
remained significant in multivariate analysis. This finding was perhaps
unexpected as although platinum sensitivity is significantly associated
with overall survival (P = 3.64 9 1018) its link with progression-free
survival is even stronger (P = 3.77 9 1037). The association
between high calpain-2 expression and overall survival is independent
of platinum sensitivity which suggests that any effect calpain-2 expres-
sion exerts upon clinical endpoint is not solely due to modulation of
the cellular response to platinum-based chemotherapy. Advanced
mucinous ovarian carcinoma has been shown to have a poorer
response to platinum-based chemotherapy [27, 28]. In this study, we
do observe a difference between histological type and platinum resis-
tance (v2 = 13.724, d.f. = 4, P = 0.008), however, there are insuffi-
Table 2 Cox proportional hazards analysis for progression-free (A)
and overall-survival (B) for calpain-2 expression. Exp (B) is used to
denote hazard ratio, and 95% CI is used to denote 95% confidence
interval
P-value Exp (B)
95% CI for
Exp (B)
Upper Lower
(A) Progression-free survival
Calpain-2 expression 0.880 0.955 0.524 1.739
Grade 0.254 1.320 0.820 2.124
Stage 0.001 1.891 1.321 2.706
Optimal debulking 0.861 1.057 0.570 1.961
Platinum sensitivity 0.000 9.025 4.696 17.345
(B) Overall survival
Calpain-2 expression 0.018 2.174 1.144 4.130
Grade 0.060 1.676 0.978 2.873
Stage 0.205 1.265 0.879 1.819
Optimal debulking 0.476 1.258 0.669 2.368
Platinum sensitivity 0.000 4.938 2.462 9.904
A
B
C
Fig. 3 Kaplan–Meier analysis of overall survival showing the impact of
calpastatin (A), calpain-1 (B) and calpain-2 (C) expression in cohort of
154 patients with significance determined using the log rank test. (A)
low expression group has 38 observations and 19 events and high
expression group has 80 observations and 37 events; (B) low expres-
sion group has 19 observations and 10 events and high expression
group has 99 observations and 45 events; (C) low expression group
has 40 observations and 13 events and high expression group has 78
observations and 44 events; where observations are the number of
observations per group and events are those patients who died.
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cient cases of alternate histological subtype to perform subset analysis
of calpain expression and clinical outcome in these groups.
In summary, high expression of calpain-2 is significantly associ-
ated with resistance to platinum-based adjuvant chemotherapy.
Furthermore, high calpain-2 expression is significantly associated
with both poor progression-free and overall survival. The association
between high calpain-2 expression and overall survival remains sig-
nificant in multivariate analysis. Determining calpain-2 expression in
ovarian cancer patients prior to platinum-based chemotherapy may
identify those patients whose tumours are at high risk of developing
resistance to the chemotherapy regimen and identification of such
individuals will allow more rigorous follow-up or alternate treatment
regimens to be considered. The findings of this study warrant valida-
tion in a larger clinical cohort.
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